Decipher Bladder Genomic Classifier



What is Decipher Bladder?


Decipher Bladder is:

- A transcriptomic subtyping tool that provides a deep biological characterization of your patients' bladder cancer
- Intended for men and women diagnosed with:
 - high-grade T1 non-muscle invasive bladder cancer through T4a muscle invasive bladder cancer
 - and who are candidates for definitive local therapy
- Derived from 219 genes
- Performed on tumor tissue collected during a trans urethral resection of a bladder tumor (TURBT)



Decipher Bladder provides the tumor molecular subtype of your patient's bladder cancer, which:

- May help determine a patient's risk of upstaging at time of radical cystectomy¹
- May help identify patients who might benefit most from cisplatinbased neoadjuvant chemotherapy (NAC) prior to radical cystectomy²
- Identifies patients with neuroendocrinelike tumors, which are associated with a poor prognosis and may benefit from rapid referral to medical oncology³
- May be useful in identifying optimal candidates for immune checkpoint inhibitor therapy⁴



The Decipher Bladder Report

PAGE 1

PATIENT Name: Sample Patient Date of Birth: -/-/ Medical Record #: Sex: _		SPECIMEN INFORMATION Order Date:// Specimen ID: Specimen Received Date: -/-/ Accession ID: MC-123456		ORDERING PHYSICIAN Name: Sample Physician, MD Clinic: Sample Clinic Address: 123 Birch Avenue, Suite / Anytown, CA 54321		
CLINICAL AND PATHOLOGY DETAILS For reference only, not used in calculation of genomic subtype Date of Procedure: 01/02/2021 Tumor Type: Muscle Invasive Bladder Carcinoma Specimen Type: TURBT Tumor Stage: cT2						
DECIR	PHER GENOMIC RESULTS	S				
UMINAL	Luminal	BLADDER CANCER SUBTYPE: LUMINAL				
LUM LUM			INTERPRETATION			
I		Luminal subtype bladder cancer is associated with a more favorable prognosis. ¹² In comparison with non-luminal subtype disease:				
NON-LUMINAL	Infiltrated [†]	Risk of Upstaging		der cancer is more likely to negative and pT2 or less) at radio		
	Basal	Benefit from NAC [‡]	Patients with luminal subtype muscle-invasive bladde cancer may receive less benefit from cisplatin-base neoadjuvant chemotherapy (NAC). ³			
	Basal Claudin-Low					
	Neuroendocrine- Like					
i						
ab Direct aboratory	tor Name, MD] y Director		Report Date			
	05D2055897 Luminal In	filtrated *Neoadjuvant cher		performance characteristics determined by Veracyte Labs S		





Molecular Subtype

- The molecular subtype in which the patient tumor has the highest probability of belonging
- Luminal tumors tend to be associated with less aggressive disease while non-luminal tend to be associated with more aggressive disease




Interpretation

- Summary based on the patient's tumor molecular subtype and relevant clinical findings
- Includes the risk of upstaging the patient may have at RC and benefit from NAC prior to RC

The Decipher Bladder Report

PAGE 2







Subtype Probabilities

The probabilities of the patient tumor belonging to each of the 5 molecular subtypes



Clinical Findings

Clinical study results relevant to this patient



Test Description

An overview of how the test is performed



Intended Use

Decipher Bladder is intended for use in patients with AJCC Stage I to IIIA bladder cancer who are candidates for definitive therapy



References

References for each of the clinical studies cited in the report.

How to Order Decipher Bladder

Email

orders@decipherbio.com

Fax 1.858.766.6575

Contact Customer Support

Phone: 1.888.792.1601 Email: cs@decipherbio.com

What to Include

- Requisition form
- Pathology report
- Demographic information
 Office notes

Sample Types Accepted

- TURBT and
- Patient has not received local therapy

What to Expect from the Testing Process



Physician orders Decipher



Decipher handles tissue collection, processing, and analysis as well as billing to insurance



Decipher Bladder report generated and sent to ordering physician

Decipher Testing Insurance Coverage

Medicare covers Decipher Bladder for men and women with AJCC Stage I to IIIA bladder cancer Financial assistance is available via the **Decipher Assist Program*** *see page 11

AJCC Stage **Stage Grouping** Medicare Coverage 0a Ta, N0, M0 0is Tis (CIS), NO, MO \checkmark Т T1, N0, M0 T2a/T2b, N0, M0 II T3a/T3b/T4a, N0, M0 TTTA **OR** T1-4a, N1, M0 IIIB T1-T4a, N2/N3, M0 IVA T4b, Any N, M0 IVB Any T, Any N, M1b



How Veracyte Handles the Insurance Process

step 1	A claim is submitted to your patient's insurer
step 2	The patient will receive an Explanation of Benefits (EOB) from insurer* *This is not a bill
step 3	In many cases, insurance pays for the complete cost of the test
step 4	In the event the patient's insurance company does not pay for the complete cost of the test, Decipher will appeal it on their behalf
step 5	After the appeal, if the patient's balance exceeds \$395, a Decipher Representative will guide them through their options

Veracyte's Decipher Assist

We are committed to ensuring access for all eligible patients

We offer two programs to ensure testing is affordable for patients:

- **1. Financial assistance** for patients with demonstrated financial need
- 2. Tailored payment plans to accommodate certain financial circumstances

Financial Assistance

Designed for qualified patients with commercial insurance

- Patients may be eligible for a reduction to non-covered costs
- Eligibility requirements include:
 - Determination of medical necessity for Decipher testing by a physician
 - Completed Decipher Assist application
 - Financial qualification

Payment Plans

Customized for patients at specific income levels

Household	COST TO PATIENT						
Size	\$0	\$100	\$295				
1	\$40,770	\$54,360	\$67,950				
2	\$54,930	\$73,240	\$91,550				
3	\$69,090	\$92,120	\$115,150				
4	\$83,250	\$111,000	\$138,750				
5	\$97,410	\$129,880	\$162,350				
maximum household income*							

*Decipher Assist eligibility is based on total annual household income, insurance status, and household size. Some eligibility restrictions apply.

Decipher Assist offers certain Decipher tests at a reduced cost to eligible applicants except where otherwise restricted. Residents of the United States, District of Columbia and Puerto Rico are eligible to apply. Decipher Assist does not constitute health insurance. You must meet certain income requirements set forth above. We may request documentation to verify your income, including recently filed tax returns and other supporting documentation. By requesting assistance, you certify, to the best of your knowledge, that you are eligible for assistance and that you have insufficient financial resources to pay for the ordered test. We may discontinue or change this program at any time for any reason without notice.



To learn more about Decipher Bladder contact us today at **1.888.792.1601** or **cs@decipherbio.com**

REFERENCES:

- Lotan Y et al., Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. European Association of Urology, Vol. 76, Issue 2, 2019, Pages 200-206. https://doi.org/10.1016/j.eururo.2019.04.036
- Lotan Y et al., Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. The Journal of Urology, Vol. 207, 2021, Pages 541-550. ww.auajournals.org/ doi/10.1097/JU.00000000002261.
- Grivas P et al., Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, Vol. 38, Issue 4, 2020, Pages 262-268. https://doi.org/10.1016/j.urolonc.2019.11.004.
- 4. Necchi A et al., Molecular Subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Urologic Oncology: Seminars and Original Investigations, Vol. 39, Issue 10, 2021, Pages 734.e11-735.e17. https://doi.org/10.1016/j.urolonc.2021.06.011.

© 2023 Veracyte, Inc. All rights reserved, Decipher, Veracyte, and the Veracyte logo are registered trademarks of Veracyte. MRKT-FRM-10043